BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21415707)

  • 1. Epigenetic modifications of histone h4 in lung neuroendocrine tumors.
    Li F; Ye B; Hong L; Xu H; Fishbein MC
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):389-94. PubMed ID: 21415707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
    Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
    J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
    Travis WD
    Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations of neuroendocrine tumours of the lung.
    Rossi G; Bertero L; Marchiò C; Papotti M
    Histopathology; 2018 Jan; 72(1):142-152. PubMed ID: 29239031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
    Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
    Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.
    Cho NH; Koh ES; Lee DW; Kim H; Choi YP; Cho SH; Kim DS
    J Proteome Res; 2006 Mar; 5(3):643-50. PubMed ID: 16512680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary neuroendocrine tumors: an entity in search of cytologic criteria.
    Huang CC; Collins BT; Flint A; Michael CW
    Diagn Cytopathol; 2013 Aug; 41(8):689-96. PubMed ID: 23166111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrine tumors of the lung].
    Takei H; Asamura H
    Nihon Rinsho; 2004 May; 62(5):877-82. PubMed ID: 15148812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
    Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
    BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
    Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.